The Technical Analyst
Evoke Pharma Inc [EVOK]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Evoke Pharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-8.94% $0.469
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.97 mill |
| EPS: | -2.33 |
| P/E: | -0.200 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 8.48 mill |
| Avg Daily Volume: | 0.0474 mill |
| RATING 2024-04-19 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.200 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.200 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.427 - 0.569 ( +/- 14.26%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-05-10 | Widder Kenneth J | Buy | 14 250 | Stock Option (Right to Buy) |
| 2023-05-10 | Reed Vickie S | Buy | 15 000 | Stock Option (Right to Buy) |
| 2023-05-10 | Hill Malcolm R | Buy | 14 625 | Stock Option (Right to Buy) |
| 2023-05-10 | Garner Cam L | Buy | 17 750 | Stock Option (Right to Buy) |
| 2023-05-10 | Brady Todd C | Buy | 14 625 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 99 transactions |
| Buy: 6 847 814 | Sell: 1 253 905 |
Forecast:
16:00 - $0.469
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.469
Forecast 2: 16:00 - $0.469
Forecast 3: 16:00 - $0.469
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.469 (-8.94% ) |
| Volume | 0.0019 mill |
| Avg. Vol. | 0.0474 mill |
| % of Avg. Vol | 3.99 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EVOK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EVOK
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Latest Press Releases
2024-04-17 08:30:00 - Press Release
Evoke Pharma To Host Virtual Key Opinion Leader (kol) Webinar On The Evolving Landscape Of Gastroparesis: Gimoti, Hospitalizations, And Glp-1 Medications
Michael cline, do., medical director gastroparesis clinic, cleveland clinic to present michael cline, do., medical director gastroparesis clinic, cleveland clinic to present
2024-03-21 16:15:00 - Press Release
Evoke Pharma Announces Senior Leadership Transition With Promotion Of Matthew J. D'onofrio To Chief Executive Officer
Solana beach, calif., march 21, 2024 (globe newswire) -- evoke pharma, inc. (nasdaq: evok), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (gi) diseases with an emphasis on gimoti® (metoclopramide) nasal spray, announced that matthew j. d'onofrio will be succeeding david a. gonyer as chief executive officer as of march 31, 2024 upon mr. gonyer's departure for personal reasons. mr. d'onofrio currently serves as president and chief operating officer.
2024-03-14 16:05:00 - Press Release
Evoke Pharma Reports Fourth Quarter And Full Year 2023 Financial Results
Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2m, a 107% increase from 2022
2024-03-07 16:10:00 - Press Release
Evoke Pharma To Report Fourth Quarter And Full Year 2023 Results On March 14, 2024
Solana beach, calif., march 07, 2024 (globe newswire) -- evoke pharma, inc. (nasdaq: evok), a specialty pharmaceutical company focused on treatments for gastrointestinal (gi) diseases with an emphasis on gimoti® (metoclopramide) nasal spray, today announced that the company is scheduled to release its fourth quarter and full year 2023 on thursday, march 14, 2024, after the market closes.
2024-02-14 07:30:00 - Press Release
Evoke Pharma Announces Closing Of $7.5 Million Public Offering
Potential for additional $22.5 million in the event of exercise of common warrants in full potential for additional $22.5 million in the event of exercise of common warrants in full
Latest News
2024-03-14 21:33:12 - Seeking Alpha
Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript
2024-03-07 16:10:00 - GlobeNewsWire
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
SOLANA BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2023 on Thursday, March 14, 2024, after the market closes.
2023-03-21 18:39:15 - Seeking Alpha
Evoke Pharma, Inc. (EVOK) Q4 2022 Earnings Call Transcript
Evoke Pharma, Inc. (NASDAQ:EVOK ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Daniel Kontoh-Boateng - Investor Relations David Gonyer - Chief Executive Officer Chris Quesenberry - GIMOTI's Chief Commercial Officer, EVERSANA Matthew D'Onofrio - Chief Business Officer Conference Call Participants Yale Jen - Laidlaw & Company Operator Good afternoon, and welcome to the Evoke Pharma's Fourth Quarter and Full Year 2022 Earnings Conference Call. Currently, all callers have been placed in listen-only mode, and following management's prepared remarks, the call will be opened for questions.
2023-03-15 08:30:00 - GlobeNewsWire
Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023
SOLANA BEACH, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023, after the market closes.
2022-11-09 20:46:06 - Seeking Alpha
Evoke Pharma, Inc. (EVOK) Q3 2022 Results - Earnings Call Transcript
Evoke Pharma, Inc. (NASDAQ:EVOK ) Q3 2022 Results Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Daniel Kontoh-Boateng - Investor Relations, DKB Partners David Gonyer - President and Chief Executive Officer Chris Quesenberry - Chief Commercial Officer Matthew D'Onofrio - Executive Vice President, Chief Business Officer, Secretary and Treasurer Conference Call Participants Operator Good afternoon. And welcome to the Evoke Pharma Third Quarter 2022 Earnings Conference Call.
2022-11-02 08:30:00 - GlobeNewsWire
Evoke Pharma to Report Third Quarter Results on November 9, 2022
SOLANA BEACH, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its third quarter on Wednesday, November 9, 2022, after the market closes.
2022-09-06 08:30:00 - GlobeNewsWire
Evoke Pharma to Participate in H.C. Wainwright 24th Annual Global Investment Conference
SOLANA BEACH, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that the Company's President and CEO, David A. Gonyer, R.Ph., and Chief Business Officer, Matt D'Onofrio, MBA, will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place from September 12-14, 2022, at the Lotte New York Palace Hotel in NYC.
2022-08-10 18:56:05 - Seeking Alpha
Evoke Pharma, Inc. (EVOK) CEO David Gonyer on Q2 2022 Results - Earnings Call Transcript
Evoke Pharma, Inc. (NASDAQ:EVOK ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants David Gonyer – Chief Executive Officer Chris Quesenberry – Chief Commercial Officer Matthew D'Onofrio – Chief Business Officer Conference Call Participants Unidentified Company Representative Good afternoon. And thank you for participating in Evoke Pharma's conference call today.
2022-08-03 08:30:00 - GlobeNewsWire
Evoke Pharma to Report Second Quarter Results on August 10, 2022
SOLANA BEACH, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its second quarter on Wednesday, August 10, 2022, after the market closes.
2022-06-20 16:47:29 - PennyStocks
Biotech Penny Stocks Investing Guide
What to know about trading biotech stocks in 2022 The post Biotech Penny Stocks Investing Guide appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.